Sugi Predict

Sugi Predict / Compounds / SCHEMBL194039

SCHEMBL194039

SCHEMBL194039

CC(C)Nc1ccc(C(=O)c2ccc(NC(C)C)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 1/20 0.53
▸ ALDH1A1 P00352 7/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ HPGD P15428 5/20 0.52
▸ RAB9A P51151 4/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ HTT P42858 2/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ TDP1 Q9NUW8 2/20 0.50
▸ LMNA P02545 5/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ RECQL P46063 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ MAPK13 O15264 1/20 0.47
▸ MAPK12 P53778 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615179 0.92 ALDH1A1 (0.65) ALDH1A1L3MBTL1HPGDRAB9ASMN1; SMN2
SCHEMBL6842263 0.87 ALDH1A1 (0.66) RXFP1ALDH1A1L3MBTL1HPGDRAB9A
SCHEMBL1663456 0.84 HCAR3 (0.55) RXFP1ALDH1A1L3MBTL1HPGDSMN1; SMN2
SCHEMBL14830545 0.84 ALDH1A1 (0.50) RXFP1ALDH1A1L3MBTL1HPGDRAB9A
SCHEMBL10055051 0.84 RXFP1 (0.56) RXFP1ALDH1A1L3MBTL1HPGDRAB9A
SCHEMBL6841746 0.83 KMT2A (0.55) RXFP1ALDH1A1RAB9AHTTNPSR1
SCHEMBL29102032 0.83 RXFP1 (0.50) RXFP1ALDH1A1L3MBTL1HPGDRAB9A
SCHEMBL10024338 0.83 RXFP1 (0.50) RXFP1ALDH1A1L3MBTL1HPGDRAB9A
SCHEMBL13841105 0.83 HSD17B10 (0.51) RXFP1ALDH1A1L3MBTL1RAB9ASMN1; SMN2
SCHEMBL24611718 0.82 PARP10 (0.51) RXFP1ALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11382868-B2 Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same ICURE PHARMACEUTICAL INC. (KR) 2022-07-12 — — US claimed
EP-3200754-B1 COSMETIC PROCESS FOR ATTENUATING WRINKLES OREAL (FR) 2020-06-10 — — EP claimed
US-20190046463-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME ICURE PHARMACEUTICAL INC. (KR) 2019-02-14 — — US claimed
EP-3415141-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME Icure Pharmaceutical Inc. (KR) 2018-12-19 — — EP claimed
US-20180044560-A1 HIGH TEMPERATURE STABLE, LOW OUTGASSING COMPOSITION, PROTECTIVE TAPE COMPRISING SUCH COMPOSITION AND USE OF SUCH TAPE WITH THIN GLASS CORNING INC (US) 2018-02-15 — — US claimed
EP-3200754-A1 COSMETIC PROCESS FOR ATTENUATING WRINKLES L'OREAL (FR) 2017-08-09 — — EP claimed
US-20170209360-A1 COSMETIC PROCESS FOR ATTENUATING WRINKLES L'OREAL (FR) 2017-07-27 — — US claimed
WO-2016050793-A1 COSMETIC PROCESS FOR ATTENUATING WRINKLES L'OREAL (FR) 2016-04-07 — — WO claimed
US-20070232714-A1 Device having low outgassing photo or electron beam curable rubbery polymer material CORNING INCORPORATED 2007-10-04 — — US claimed
EP-1817390-A2 DEVICE COMPRISING LOW OUTGASSING PHOTO OR ELECTRON BEAM CURED RUBBERY POLYMER MATERIAL Corning Incorporated (US) 2007-08-15 — — EP claimed
US-7232595-B2 Device comprising low outgassing photo or electron beam cured rubbery polymer material CORNING INCORPORATED (US) 2007-06-19 — — US claimed
WO-2006060592-A2 DEVICE COMPRISING LOW OUTGASSING PHOTO OR ELECTRON BEAM CURED RUBBERY POLYMER MATERIAL CORNING INCORPORATED (US) 2006-06-08 — — WO claimed
US-20050152595-A1 Device comprising low outgassing photo or electron beam cured rubbery polymer material CORNING INCORPORATED 2005-07-14 — — US claimed
US-6797841-B2 HAVING PHOTOINITIATION ACTIVITY WITH MINIMAL OR NO ADVERSE HAZARDOUS CHARACTERISTICS ALBEMARLE CORPORATION 2004-09-28 — — US claimed
US-6762323-B2 EXPOSING A FORMUALTION CONTAINING A PIGMENT AND A PHOTOPOLYMERIZABLE COMPOUND HAVING AN ETHYLENICALLY UNSATURATED DOUBLE BOND TO RADIATION IN PRESENCE NON-MUTAGENIC PHOTOINITIATOR ALBEMARLE CORPORATION 2004-07-13 — — US claimed
US-20040092618-A1 Low outgassing photo or electron beam curable rubbery polymer material, preparation thereof and device comprising same CORNING INCORPORATED 2004-05-13 — — US claimed
US-20040054244-A1 Process of quadricyclane production EXCITON, INC. 2004-03-18 — — US claimed
US-20030078313-A1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2003-04-24 — — US claimed
US-20030065049-A1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2003-04-03 — — US claimed
US-6479706-B1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2002-11-12 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170209360-A1 COSMETIC PROCESS FOR ATTENUATING WRINKLES CUTA, MC1R, GLA RXFP1 1118/4885ALDH1A1 1493/4885L3MBTL1 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.